Key result
MAO-A inhibition mitigates ischemic ventricular dysfunction in mice by preventing 4-HNE accumulation and Ca2+ overload.
Why the study?
The sources of mitochondrial 4-HNE in cardiac diseases and its mechanisms of action remain poorly understood.
MAO-A activation contributes to postischemic cardiac remodeling through local 4-HNE production and mitochondrial calcium overload, suggesting MAO-A as a potential therapeutic target for heart failure.
Hypothesis-generating for MAO-A inhibition in ischemic HF; leaves open translation to human outcomes.
Chronic remodeling postmyocardial infarction consists in various maladaptive changes including interstitial fibrosis, cardiomyocyte death and mitochondrial dysfunction that lead to heart failure (HF). Reactive aldehydes such as 4-hydroxynonenal (4-HNE) are critical mediators of mitochondrial dysfunction but the sources of mitochondrial 4-HNE in cardiac diseases together with its mechanisms of action remain poorly understood. Here, we evaluated whether the mitochondrial enzyme monoamine oxidase-A (MAO-A), which generates H 2 O 2 as a by-product of catecholamine metabolism, is a source of deleterious 4-HNE in HF. We found that MAO-A activation increased mitochondrial ROS and promoted local 4-HNE production inside the mitochondria through cardiolipin peroxidation in primary cardiomyocytes. Deleterious effects of MAO-A/4-HNE on cardiac dysfunction were prevented by activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2), the main enzyme for 4-HNE metabolism. Mechanistically, MAO-A-derived 4-HNE bound to newly identified targets VDAC and MCU to promote ER-mitochondria contact sites and MCU higher-order complex formation. The resulting mitochondrial Ca 2+ accumulation participated in mitochondrial respiratory dysfunction and loss of membrane potential, as shown with the protective effects of the MCU inhibitor, RU360. Most interestingly, these findings were recapitulated in a chronic model of ischemic remodeling where pharmacological or genetic inhibition of MAO-A protected the mice from 4-HNE accumulation, MCU oligomer formation and Ca 2+ overload, thus mitigating ventricular dysfunction. To our knowledge, these are the first evidences linking MAO-A activation to mitoCa 2+ mishandling through local 4-HNE production, contributing to energetic failure and postischemic remodeling.
No takes yet. Share an insight, caveat, or question.
Santin et al. (2019) studied Chronic postischemic cardiac remodeling. Pharmacological or genetic inhibition of MAO-A was evaluated on Ventricular dysfunction, 4-HNE accumulation, and Ca2+ overload. Inhibition of MAO-A protected mice from 4-HNE accumulation, MCU oligomer formation, and Ca2+ overload, mitigating ventricular dysfunction in a chronic ischemic remodeling model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: